Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23652063 | 0.85 | LMNA (0.31) | SMN1; SMN2 | |
| SCHEMBL18377905 | 0.82 | DPP4 (0.31) | — | |
| SCHEMBL18377713 | 0.82 | DPP4 (0.31) | — | |
| SCHEMBL24908627 | 0.82 | — | — | |
| SCHEMBL21538542 | 0.81 | ACHE (0.35) | ACHECYP19A1 | |
| SCHEMBL3056144 | 0.78 | — | — | |
| SCHEMBL21419598 | 0.78 | ACHE (0.36) | ACHECYP19A1 | |
| SCHEMBL20926022 | 0.78 | CYP19A1 (0.40) | ACHECYP19A1 | |
| SCHEMBL18755609 | 0.78 | ACHE (0.36) | ACHECYP19A1 | |
| SCHEMBL20644610 | 0.77 | ACHE (0.30) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196875-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2017053769-A1 | TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-03-30 | — | — | WO | disclosed |
| US-20130071536-A1 | COMPOUNDS COMPRISING LINKED HETEROARYL MOIETIES AND THEIR USE AS NOVEL UMAMI FLAVOR MODIFIERS, TASTANTS AND TASTE ENHANCERS FOR COMESTIBLE COMPOSITIONS | SENOMYX, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20100267596-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASE SE (DE) | 2010-10-21 | — | — | US | disclosed |
| EP-2229365-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASF SE (DE) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077452-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASF SE (DE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267596-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | LIPA, IDE, CEL | ACHE 44/4885ALDH1A1 997/4885SMN1; SMN2 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.